David Krempa Sells 16,977 Shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Stock

Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Get Free Report) insider David Krempa sold 16,977 shares of the company's stock in a transaction on Thursday, June 12th. The shares were sold at an average price of $14.92, for a total transaction of $253,296.84. Following the completion of the sale, the insider now directly owns 629,669 shares of the company's stock, valued at $9,394,661.48. This trade represents a 2.63% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

David Krempa also recently made the following trade(s):

• On Monday, June 16th, David Krempa sold 10,223 shares of Eton Pharmaceuticals stock. The stock was sold at an average price of $14.73, for a total transaction of $150,584.79.
• On Friday, June 13th, David Krempa sold 6,800 shares of Eton Pharmaceuticals stock. The shares were sold at an average price of $14.77, for a total transaction of $100,436.00.

Eton Pharmaceuticals Stock Down 0.9%

Shares of NASDAQ:ETON traded down $0.13 during midday trading on Monday, hitting $14.17. 324,095 shares of the stock traded hands, compared to its average volume of 224,421. The business's 50 day moving average is $16.54 and its two-hundred day moving average is $15.05. The stock has a market capitalization of $380.01 million, a PE ratio of -64.41 and a beta of 1.28. Eton Pharmaceuticals, Inc. has a one year low of $3.18 and a one year high of $21.48.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.09 by ($0.02). The business had revenue of $17.28 million for the quarter, compared to analysts' expectations of $14.33 million. Eton Pharmaceuticals had a negative net margin of 15.81% and a negative return on equity of 36.29%. As a group, sell-side analysts forecast that Eton Pharmaceuticals, Inc. will post -0.14 earnings per share for the current year.

Institutional Investors Weigh In On Eton Pharmaceuticals

Large investors have recently made changes to their positions in the business. Nantahala Capital Management LLC lifted its stake in Eton Pharmaceuticals by 5.1% in the first quarter. Nantahala Capital Management LLC now owns 1,175,951 shares of the company's stock worth $15,264,000 after acquiring an additional 57,468 shares during the period. Mink Brook Asset Management LLC bought a new position in Eton Pharmaceuticals in the 4th quarter worth $6,071,000. Acadian Asset Management LLC lifted its position in shares of Eton Pharmaceuticals by 61.9% in the 1st quarter. Acadian Asset Management LLC now owns 402,428 shares of the company's stock worth $5,219,000 after purchasing an additional 153,923 shares during the period. Cannell Capital LLC bought a new stake in shares of Eton Pharmaceuticals during the 4th quarter valued at about $5,079,000. Finally, Millennium Management LLC boosted its stake in shares of Eton Pharmaceuticals by 156.3% during the 1st quarter. Millennium Management LLC now owns 355,929 shares of the company's stock valued at $4,620,000 after purchasing an additional 217,042 shares in the last quarter. 27.86% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently commented on ETON shares. HC Wainwright reiterated a "buy" rating and issued a $35.00 price objective (up previously from $33.00) on shares of Eton Pharmaceuticals in a report on Thursday, May 29th. Craig Hallum lifted their price target on Eton Pharmaceuticals from $26.00 to $28.00 and gave the stock a "buy" rating in a research note on Wednesday, May 14th. Finally, B. Riley reiterated a "buy" rating and issued a $26.00 price objective (up previously from $24.00) on shares of Eton Pharmaceuticals in a research report on Friday, May 16th.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.